EZH2 and leukemia: These in vivo data suggested that EZH2 inhibition by chidamide or shEZH2 decreased leukemia growth and increased the antileukemia effect of adriamycin through suppression of Smo/Gli-1 pathway in the leukemia-bearing mouse models.